Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors
Our translational QSP platform offers an innovative pathway to integrate multiscale knowledge and inform clinical decision-making of novel solid tumor-targeting CAR-T therapies.
Authors
- Yiyang Xu
- Laura Sun (ORCID: https://orcid.org/0000-0001-5226-1817)
- Chen Zhao (ORCID: https://orcid.org/0000-0003-1361-8419)
- Qiu-Chuan Zhuang
- Qi Rao
- Wenjie Wang (ORCID: https://orcid.org/0000-0002-1842-3576)
- Jie Mao (ORCID: https://orcid.org/0000-0002-6410-6651)
- Sujie Zhang (ORCID: https://orcid.org/0000-0002-6852-7090)
- Yuchen Qu (ORCID: https://orcid.org/0000-0002-0649-3147)
- Da Xu (ORCID: https://orcid.org/0000-0003-3565-7128)
- S. Yang (ORCID: https://orcid.org/0009-0008-9976-1614)
- Dong Geng
Institutions
- 490 BioTech (United States) (US)
- Viva Biotech (China) (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012331
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- National Natural Science Foundation of China
- Nanjing Medical University